References
- Wang L, Zhang S, Wang X . The metabolic mechanisms of breast cancer metastasis. Front Oncol. 2020;10:602416.
- Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol. 2020;21:e342–e349.
- Chen W, Zheng R, Zeng H, et al. Annual report on status of cancer in China, 2011. Chin J Cancer Res. 2015;27:2–12.
- Liu Y, Dou M, Song X, et al. The emerging role of the piRNA/piwi complex in cancer. Mol Cancer. 2019;18:123.
- Erber R, Meyer J, Taubert H, et al. PIWI-Like 1 and PIWI-like 2 expression in breast cancer. Cancers (Basel). 2020;12:2742.
- Vychytilova-Faltejskova P, Stitkovcova K, Radova L, et al. Circulating PIWI-interacting RNAs piR-5937 and piR-28876 are promising diagnostic biomarkers of colon cancer. Cancer Epidemiol Biomarkers Prev. 2018;27:1019–1028.
- Zhou X, Liu J, Meng A, et al. Gastric juice piR-1245: a promising prognostic biomarker for gastric cancer. J Clin Lab Anal. 2020;34:e23131.
- Zhang L, Meng X, Pan C, et al. piR-31470 epigenetically suppresses the expression of glutathione S-transferase pi 1 in prostate cancer via DNA methylation. Cell Signal. 2020;67:109501.
- Fu A, Jacobs DI, Hoffman AE, et al. PIWI-interacting RNA 021285 is involved in breast tumorigenesis possibly by remodeling the cancer epigenome. Carcinogenesis. 2015;36:1094–1102.
- Yao J, Wang YW, Fang BB, et al. piR-651 and its function in 95-D lung cancer cells. Biomed Rep. 2016;4:546–550.
- Li PF, Chen SC, Xia T, et al. Non-coding RNAs and gastric cancer. World J Gastroenterol. 2014;20:5411–5419.
- Zhang H, Ren Y, Xu H, et al. The expression of stem cell protein Piwil2 and piR-932 in breast cancer. Surg Oncol. 2013;22:217–223.
- Cheng J, Guo JM, Xiao BX, et al. piRNA, the new non-coding RNA, is aberrantly expressed in human cancer cells. Clin Chim Acta. 2011;412:1621–1625.
- Li D, Luo Y, Gao Y, et al. piR-651 promotes tumor formation in non-small cell lung carcinoma through the upregulation of cyclin D1 and CDK4. Int J Mol Med. 2016;38(3):927–936.
- Nebbioso A, Tambaro FP, Dell’Aversana C, et al. Cancer epigenetics: moving forward. PLoS Genet. 2018;14:e1007362.
- Wang YP, Lei QY. Metabolic recoding of epigenetics in cancer. Cancer Commun (Lond). 2018;38:25.
- Lyko F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2018;19:81–92.
- Leppert S, Matarazzo MR. De novo DNMTs and DNA methylation: novel insights into disease pathogenesis and therapy from epigenomics. Curr Pharm Des. 2014;20:1812–1818.
- Álvarez-Garcia V, Tawil Y, Wise HM, et al. Mechanisms of PTEN loss in cancer: it’s all about diversity. Semin Cancer Biol. 2019;59:66–79.
- Bertrand FE, McCubrey JA, Angus CW, et al. NOTCH and PTEN in prostate cancer. Adv Biol Regul. 2014;56:51–65.
- Zhang B, Zhang X, Jin M, et al. CagA increases DNA methylation and decreases PTEN expression in human gastric cancer. Mol Med Rep. 2019;19:309–319.
- Yang J, Zuo X, Bai W, et al. PTEN methylation involved in benzene-induced hematotoxicity. Exp Mol Pathol. 2014;96:300–306.
- Zhao D, Lu X, Wang G, et al. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature. 2017;542:484–488.
- Phuong NT, Kim SK, Lim SC, et al. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat. 2011;130:73–83.
- Haupt S, Vijayakumaran R, Miranda PJ, et al. The role of MDM2 and MDM4 in breast cancer development and prevention. J Mol Cell Biol. 2017;9:53–61.
- Maeda A, Irie K, Hashimoto N, et al. Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report. Invest New Drugs. 2021;39:272–277.
- Holah NS, Hemida AS. Cyclin D1 and PSA act as good prognostic and clinicopathological indicators for breast cancer. J Immunoassay Immunochem. 2020;41:28–44.